|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-3-7
|
|
pubmed:abstractText |
Novel antibody-based immunotherapeutic strategies exploit chimeric immune receptors (CIR), expressed on the surface of transduced human peripheral blood mononuclear cells (PBMC), to redirect potent non-MHC-dependent cytotoxicity to tumor cells expressing a tumor-associated antigen. However, clinical application of the strategy has been hampered by the potential side effects associated with immunogenicity and by low transduction efficiency.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Chromium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Variable Region,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazolium Salts,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/thiazolyl blue
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1099-498X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2004 John Wiley & Sons, Ltd.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
158-70
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15538730-Antibodies, Monoclonal,
pubmed-meshheading:15538730-Antigens, CD3,
pubmed-meshheading:15538730-Blotting, Western,
pubmed-meshheading:15538730-Cell Line, Tumor,
pubmed-meshheading:15538730-Cell Proliferation,
pubmed-meshheading:15538730-Chromium Radioisotopes,
pubmed-meshheading:15538730-DNA Primers,
pubmed-meshheading:15538730-Flow Cytometry,
pubmed-meshheading:15538730-Fluorescent Antibody Technique,
pubmed-meshheading:15538730-Gene Therapy,
pubmed-meshheading:15538730-Gene Transfer Techniques,
pubmed-meshheading:15538730-Genetic Vectors,
pubmed-meshheading:15538730-Humans,
pubmed-meshheading:15538730-Immunoglobulin Variable Region,
pubmed-meshheading:15538730-Immunotherapy,
pubmed-meshheading:15538730-Leukemia Virus, Gibbon Ape,
pubmed-meshheading:15538730-Lymphocytes,
pubmed-meshheading:15538730-Neoplasms,
pubmed-meshheading:15538730-Receptor, erbB-2,
pubmed-meshheading:15538730-Tetrazolium Salts,
pubmed-meshheading:15538730-Thiazoles,
pubmed-meshheading:15538730-Transduction, Genetic
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor.
|
|
pubmed:affiliation |
Molecular Therapies Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milano, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
